Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Research Smad2 and Smad6 as predictors of overall survival in oral squamous cell carcinoma patients

Full text
Author(s):
Mangone, Flavia R. R. [1] ; Walder, Fernando [2, 3] ; Maistro, Simone [1] ; Pasini, Fatima S. [1] ; Lehn, Carlos N. [2] ; Carvalho, Marcos B. [2] ; Brentani, M. Mitzi [1] ; Snitcovsky, Igor [1] ; Federico, Miriam H. H. [1]
Total Authors: 9
Affiliation:
[1] Univ Sao Paulo, Disciplina Oncol, Dept Radiol, Fac Med, LIM 24, Hosp Clin, Sao Paulo - Brazil
[2] Hosp Heliopolis, Serv Cirurgia Cabeca & Pescoco, Sao Paulo - Brazil
[3] Univ Fed Sao Paulo, Dept Otorrinolaringol, Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Molecular Cancer; v. 9, MAY 12 2010.
Web of Science Citations: 20
Abstract

Background: To test if the expression of Smad1-8 mRNAs were predictive of survival in patients with oral squamous cell carcinoma (SCC). Patients and Methods: We analyzed, prospectively, the expression of Smad1-8, by means of Ribonuclease Protection Assay in 48 primary, operable, oral SCC. In addition, 21 larynx, 10 oropharynx and 4 hypopharynx SCC and 65 matched adjacent mucosa, available for study, were also included. For survival analysis, patients were categorized as positive or negative for each Smad, according to median mRNA expression. We also performed real-time quantitative PCR (QRTPCR) to asses the pattern of TGF beta 1, TGF beta 2, TGF beta 3 in oral SCC. Results: Our results showed that Smad2 and Smad6 mRNA expression were both associated with survival in Oral SCC patients. Cox Multivariate analysis revealed that Smad6 positivity and Smad2 negativity were both predictive of good prognosis for oral SCC patients, independent of lymph nodal status (P = 0.003 and P = 0.029, respectively). In addition, simultaneously Smad2(-) and Smad6(+) oral SCC group of patients did not reach median overall survival (mOS) whereas the mOS of Smad2(+)/Smad6(-) subgroup was 11.6 months (P = 0.004, univariate analysis). Regarding to TGF beta isoforms, we found that Smad2 mRNA and TGF beta 1 mRNA were inversely correlated (p = 0.05, R = -0.33), and that seven of the eight TGF beta 1(+) patients were Smad2(-). In larynx SCC, Smad7(-) patients did not reach mOS whereas mOS of Smad7(+) patients were only 7.0 months (P = 0.04). No other correlations were found among Smad expression, clinico-pathological characteristics and survival in oral, larynx, hypopharynx, oropharynx or the entire head and neck SCC population. Conclusion: Smad6 together with Smad2 may be prognostic factors, independent of nodal status in oral SCC after curative resection. The underlying mechanism which involves aberrant TGF beta signaling should be better clarified in the future. (AU)